Kelly B. Pendergrass

Hematology Oncology
4881 Ne Goodview Cir
Lees Summit, MO 64064

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications

First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.

First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.

Journal: Breast (Edinburgh, Scotland)
Published: September 18, 2017

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.

Journal: Breast cancer research and treatment
Published: May 02, 2017

A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.

A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.

Journal: Blood
Published: May 08, 2014

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

Journal: Journal of the National Cancer Institute
Published: December 10, 2013

A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.

A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.

Journal: Leukemia & lymphoma
Published: January 03, 2013

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.

Journal: Breast cancer research and treatment
Published: June 27, 2012
Showing 1-6 of 6

Last Updated: 09/26/2026